

AMENDMENTS TO THE DRAWINGS

The attached sheets of drawings include changes to Figures 1, 2, 11 and 14. Please replace the originally filed Figures 1, 2, 11 and 14 (4 sheets) with the attached replacement drawings (4 sheets).

AMENDMENTS TO THE SEQUENCE LISTING

Please add the sequence listing filed herewith (156 pages).

REMARKS

I. Notice to File Missing Parts

A Notice to File Missing Parts of Nonprovisional Application was mailed on August 12, 2004. In response, submitted herewith is a copy of the Notice, an executed Inventor's Declaration, sequence listing in compliance with 37 C.F.R. §1.821-1.825 in paper and computer readable form and replacement drawings.

The Notice stated that Figures 1 and 2 have a line quality that is too light to be reproduced or the text was illegible according to 37 C.F.R. § 1084(l) and (p)(1). In addition, the notice stated that Figures 11 and 14 contained numbers, letters or reference characters that are less than 0.32 cm in height. In response, replacement drawings are submitted herewith to put the drawing in compliance with 37 C.F.R. § 1.84 and § 1.121. The replacement drawings are identical to those originally filed except for more bold lines in Figures 1 and 2 and larger text in figures 11 and 14. The replacement drawings do not add new matter to the application.

The Notice also required payment of the statutory filing fee and additional claim fees. Enclosed is a check of \$2330 for payment of the statutory filing fee (\$770), additional claims fees in view of the foregoing amendment (\$410), the missing parts surcharge (\$130), and fee for three-months extension of time (\$1020.00). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 30847/2051-004. A duplicate copy of this paper is enclosed.

II. Support for New Claims

Claims 1-205 are canceled without prejudice solely to reduce the excess claim fees, avoid a restriction requirement and to pursue claims to a preferred embodiment, and not for any reason relating to patentability. Applicants reserve the right to pursue claims of the same or similar subject matter in a continuing application. New claims 206-225 are supported throughout the specification and do not add new matter to the application.

The new claims are directed to methods of reducing C-reactive protein in a human subject. Compounds that inhibit leukotriene synthesis are described at pages 34-62 of the specification. In particular, the compounds, recited in claim 206 are supported at pages 50-52 of the specification. Physiological acceptable carriers and excipients are described, *e.g.*, at pages 70-74 of the specification.


Inflammatory markers are described, *e.g.*, at page 19, line 17 to page 20, line 7 of the specification. Methods of monitoring C-reactive protein are described, *e.g.*, in Example 5 (pp. 159-160). Methods of monitoring leukotriene synthesis and production are described, *e.g.*, in Examples 3 and 4 (pp. 149-159) and Examples 6 and 7 (pp. 160-163). Medical history and family history risk factors are described, *e.g.*, at page 20, line 8 to page 21, line 29 of the specification. FLAP (5-lipoxygenase activating protein) gene polymorphisms and FLAP genotypes and haplotypes are taught in the specification, *e.g.*, at page 15, line 25, to page 16, line 17, page 19, line 16, Example 1 (pp. 126-1470), Example 8 (pp. 163-166) and Example 9 (pages 166-192).

CONCLUSION

Prior to examination on the merits, Applicants request entry of the foregoing amendment. In addition, Applicants request that the filing fee be calculated in view of the foregoing amendment.

Dated: January 12, 2005

Respectfully submitted,

By 
Sharon M. Sintich

Registration No.: 48,484

MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Attorney for Applicant